Infectious Disease BillingComplete Coding & Revenue Guide (2026)Top CPT codes with current RVU data, denial patterns, modifier rules, bundling pitfalls, and revenue opportunities for infectious disease practices.
Top CPT Codes
The highest-value infectious disease CPT codes with current RVU data and Medicare payment from the CY 2026 Physician Fee Schedule. Click any code for the full payment, bundling, and modifier guide.
Most practices under-capture revenue on these codes through downcoding, missed modifier 25, stale fee schedules, or misapplied bundling. Our coders audit every line against the documentation before submission so the revenue earned actually gets billed.
Bundling Pitfalls
1 trapsThe code pairs that trigger NCCI edits and CO-97 denials in infectious disease. Know these before billing.
99223: 99291: Inpatient E/M (99223) + critical care (99291) same day same patient: bill ONLY one. If patient becomes critically ill after admission, bill 99291 for the critical care portion. Cannot bill both.: 87186: 87040: Susceptibility testing (87186 per organism per drug) is separately billable from culture identification (87040-87088). Bill both culture + sensitivity when both performed.: 86703: 87389: HIV antibody (86703) vs HIV-1/2 antigen/antibody combo (87389). Most screening now uses 87389 (4th generation). Cannot bill both for the same specimen.: 90378: 96372: Palivizumab (Synagis) injection: drug code (90378) + injection admin (96372). Must bill both. Drug is separately billable from admin.: 87804: 87040: Rapid test (87804 flu, 87880 strep) + culture (87040/87070) for SAME organism same day: most payers bundle rapid + culture for same pathogen. Only bill both if medically justified (rapid negative, clinical suspicion high, culture ordered).
CO-97 bundling denials are recoverable with correct modifier documentation. Most billers write them off. We work each one against the clinical record and resubmit with the right modifier 25 or 59 path.
Modifier Guidance
When to apply each modifier in infectious disease claims. Wrong modifier application is the top single-line denial trigger and a leading audit target.
Required on E/M when billing with same-day injection (antibiotic, vaccine) or lab draw. Document separately identifiable clinical problem.
Professional component — use when interpreting cultures, susceptibilities, or lab results performed at reference lab.
Distinct specimen — use when processing cultures from multiple distinct body sites (blood + urine + wound, each from different site).
Repeat test — use for repeat cultures (e.g., follow-up blood cultures to document clearance).
Repeat clinical lab test — same day repeat for same test (e.g., repeat blood glucose, repeat lactate during sepsis management).
Telemedicine — ID consultations work well via telehealth. Most payers cover established ID visits via telehealth.
CLIA waived test — for point-of-care rapid tests (flu, strep, COVID) performed under CLIA waiver.
Revenue Opportunities
6 playsThe billing codes and services most infectious disease practices under-capture. Each one is a recurring revenue lift, not a one-time fix.
Inpatient ID consultation revenue: Average ID consult (99223) pays $200-300. Follow-up visits (99232/99233) $100-200/day. With 10 consult patients and 20 follow-ups daily = $600K-1M/year for hospital-based ID.
HIV management: Each HIV patient generates 4-6 E/M visits/year ($600-1,500) + lab monitoring revenue. With 300 HIV patients = $180K-450K/year in E/M alone. Drug revenue is pharmacy benefit (not captured by physician).
Outpatient parenteral antibiotic therapy (OPAT): Managing patients on home IV antibiotics generates E/M visits 1-2x/week for 4-6 weeks per treatment course. Each course = $800-2,000 in E/M revenue.
Travel medicine: Pre-travel consultations (99214) + vaccines (multiple) generate $300-600 per traveler visit. Growing demand with international travel resumption.
Antibiotic stewardship medical directorship: Hospitals pay $50K-150K/year for ID physician stewardship director roles. 5-10 hours/week administrative time.
Hepatitis C cure: DAA therapy monitoring generates 3-4 E/M visits per treatment course (8-12 weeks). SVR confirmation at 12 weeks post-treatment. Each HCV cure course = $600-1,000 in physician E/M revenue.
Documentation Checklist
What the chart must contain to support billing. Missing documentation means audit vulnerability.
- HIV management (B20/Z21): Document viral load, CD4 count, ART regimen, resistance testing results, opportunistic infection prophylaxis status, immunization status, and adherence assessment.
- Sepsis management (A41.9/R65.20/R65.21): Document source identification, blood culture results, antibiotic selection rationale (empiric → targeted), organ dysfunction scoring (SOFA/qSOFA), lactate trending, and fluid resuscitation documentation.
- C. difficile (A04.72): Document PCR result, severity classification (non-severe, severe, fulminant), treatment selection (oral vancomycin vs fidaxomicin), and risk factor assessment (antibiotics, PPI, prior C. diff, hospitalization).
- TB management (A15/R76.11): Document TST/IGRA result, symptom assessment, CXR findings, sputum AFB results, treatment regimen (RIPE), and DOT status. Report to public health as required.
- Antibiotic stewardship: Document indication for every antibiotic prescribed, planned duration, culture results guiding therapy changes, and de-escalation rationale.
Coding Workflow
Step by step approach for coding infectious disease encounters correctly.
1. Determine encounter type: outpatient consultation (99204/99205), inpatient consult (99223), follow-up (99214/99232), or critical care (99291). 2. For HIV: bill E/M for each visit + lab orders. Monitor viral load and CD4 per treatment guidelines. ART drug costs are pharmacy benefit (Part D), not medical (Part B). 3. For inpatient: document complexity carefully — most ID consults are 99223/99233 (high complexity) due to multi-organ involvement and multiple infectious considerations. 4. For culture interpretation: 87040 (blood), 87070 (wound), 87086 (urine). Add susceptibility (87186) per organism per drug. 5. For TB: document public health reporting compliance. 6. For vaccines: bill admin (90471/90472) + vaccine product code separately.
Find the revenue leakage in your infectious disease billing.
We audit your last 90 days of infectious disease claims, surface the recoverable revenue, and work the appeals. AAPC-certified coders, specialty-specific scrub rules, no obligation.
Tired of infectious disease billing headaches?
Go Medical Billing handles Infectious Disease with AAPC-certified coders and specialty-specific scrub rules. 2.8 percent average denial rate. 2.49 percent of collections. No setup fees.
Get Your Free Billing Assessment
Free audit, no obligation. We'll review your billing and show you exactly where revenue is leaking.
Everything about Infectious Disease billing
What CPT codes does Infectious Disease bill most often?
Top Infectious Disease codes include 99214 (Established patient office visit, moderate MDM or 30-39 minutes); 99215 (Established patient office visit, high MDM or 40-54 minutes); 99213 (Established patient office visit, low MDM or 20-29 minutes); 99223 (1st hosp ip/obs high 75); 99232 (Sbsq hosp ip/obs moderate 35).
What are the most common denials in Infectious Disease billing?
Infectious Disease denials concentrate around medical necessity, bundling, prior authorization, and modifier errors.
Does Go Medical Billing handle Infectious Disease?
Yes. Go Medical Billing handles Infectious Disease billing with AAPC-certified coders, payer-specific scrub rules, and dedicated account management. Starting at 2.49 percent of collections with no setup fees.
Specialty content reviewed by AAPC-certified coders. CPT codes and descriptions are copyright of the AMA. Medicare payment varies by locality. Commercial rates vary by contract.
Free 90-Day AR Recovery Audit
We audit your last 90 days of infectious disease claims and surface revenue leakage in coding, modifier use, and bundling. AAPC-certified coders. 2.49 percent of collections. No setup fees.